

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-2498 1650; Fax: +91-22-2497 0127.

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

(Rs. in Lakhs)

Particulars	Quarter ended December 31, 2017 (Unaudited)	Quarter ended December 31, 2016 (Unaudited)	Nine months ended December 31, 2017 (Unaudited)
1 Total Income from Operations	9,566	6,916	26,368
2 Net Profit for the period (before tax, exceptional and extraordinary items)	800	110	1,597
3 Net Profit for the period before tax (after exceptional and extraordinary items)	800	110	1,597
4 Net Profit for the period after tax (after Exceptional and Extraordinary items)	546	110	1,220
5 Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	523	87	1,151
6 Paid-up equity share capital (Face Value Rs.8/- each)	1,323	1,323	1,323
7 Basic/Diluted Earnings Per Share (Rs.8/- each) - for continuing and discontinued operations (Not annualised)	3.30	0.67	7.38

Note:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 02, 2018.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- On April 1, 2017 the Company has adopted the Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from April 1, 2016. Accordingly the financial results for the quarter and nine months ended December 31, 2017 have been prepared in accordance with Ind AS and other accounting principles generally accepted in India and the results for the comparative quarter and nine months ended 31st December, 2016 have been restated in accordance with Ind AS.
- Reconciliation of results between amounts previously reported (referred to as previous GAAP) and Ind AS is presented below:

Particulars	Quarter ended 31-Dec-16	Nine months ended 31-Dec-16
Profit for the period as per previous GAAP	55	2,067
Re-measurement of revenue (a)	30	(46)
Re-measurement of Employee Benefit Net of tax (b)	23	69
Provision for Expected Credit Loss (c)	2	(11)
Other Comprehensive Income Net of Tax	110	2,079
Re-measurement of Employee Benefit Net of tax	(23)	(69)
Total Comprehensive Income for the period	87	2,010

Profit reconciliation Notes

- Provision for sales return has been made under Ind AS as per past trend of sales return to sales.
 - The remeasurement cost arising primarily due to changes in actuarial assumptions have been recognised in Other Comprehensive Income under Ind As as compared to Statement of Profit or Loss under Previous GAAP.
 - The Company has applied expected credit loss (ECL) model for measurement & recognition of impairment loss on trade and other receivables as per the provisions of IND AS 109.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on Stock Exchange websites viz. (www.nseindia.com and www.bseindia.com) and on Company's website (www.rpglifesciences.com).

For RPG Life Sciences Limited
CT. Renganathan
Managing Director
DIN-02158397

Place : Mumbai
Date : February 2, 2018



RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-2498 1650; Fax: +91-22-2497 0127

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017

(Rs. in Lakhs)

Particulars	Quarter ended	Quarter ended	Nine months ended
	December 31, 2017 (Unaudited)	December 31, 2016 (Unaudited)	December 31, 2017 (Unaudited)
1 Total Income from Operations	9,566	6,916	26,368
2 Net Profit for the period (before tax, exceptional and extraordinary items)	800	110	1,597
3 Net Profit for the period before tax (after exceptional and extraordinary items)	800	110	1,597
4 Net Profit for the period after tax (after Exceptional and Extraordinary items)	546	110	1,220
5 Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	523	87	1,151
6 Paid-up equity share capital (Face Value Rs.8/- each)	1,323	1,323	1,323
7 Basic/Diluted Earnings Per Share (Rs.8/- each) - for continuing and discontinued operations (Not annualised)	3.30	0.67	7.38

Note:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 02, 2018.
- The Company operates in only one reportable business segment i.e., Pharmaceuticals.
- On April 1, 2017 the Company has adopted the Indian Accounting Standards ('Ind AS') notified by the Ministry of Corporate Affairs with effect from April 1, 2016. Accordingly the financial results for the quarter and nine months ended December 31, 2017 have been prepared in accordance with Ind AS and other accounting principles generally accepted in India and the results for the comparative quarter and nine months ended 31st December 2016 have been restated in accordance with Ind AS.
- Reconciliation of results between amounts previously reported (referred to as previous GAAP) and Ind AS is presented below:

Particulars	Quarter ended	Nine months ended
	31-Dec-16	31-Dec-16
Profit for the period as per previous GAAP	55	2,067
Re-measurement of revenue (a)	30	(46)
Re-measurement of Employee Benefit Net of tax (b)	23	69
Provision for Expected Credit Loss (c)	2	(11)
Other Comprehensive Income Net of Tax	110	2,079
Re-measurement of Employee Benefit Net of tax	(23)	(69)
Total Comprehensive Income for the period	87	2,010

Profit reconciliation Notes

- Provision for sales return has been made under Ind AS as per past trend of sales return to sales.
 - The remeasurement cost arising primarily due to changes in actuarial assumptions have been recognised in Other Comprehensive Income under Ind As as compared to Statement of Profit or Loss under Previous GAAP.
 - The Company has applied expected credit loss (ECL) model for measurement & recognition of impairment loss on trade and other receivables as per the provisions of IND AS 109.
- 5 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on Stock Exchange websites viz. (www.nseindia.com and www.bseindia.com) and on Company's website (www.rpglifesciences.com).

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
DIN-02158397

Place : Mumbai

Date : February 2, 2018

